Get notified when KMTS files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Bain Capital Has Significant Influence Over US (new) — Bain Capital will own approximately 47.1% of common shares after the offering, giving it substantial control over corporate decisions.
- Emphasis of Matter Paragraph (new) — The auditor added an emphasis-of-matter paragraph, which signals significant uncertainty about the company's ability to continue as a going concern or other material issues.
Kestra Medical Technologies prices 6M-share IPO at $23, raising $129M net for the company
Filed December 3, 2025 · ~1 min read
Key Changes
-
high
Kestra Medical Technologies is selling 6,000,000 common shares at $23.00 per share, generating $138.0M gross proceeds before underwriting discounts and expenses.
The Offering verify on EDGAR → -
high
Net proceeds to the company are $129.0M (or $147.7M if the underwriters' option is fully exercised), after deducting underwriting discounts and estimated offering costs.
Use of Proceeds verify on EDGAR → -
medium
The company intends to use net proceeds to scale its commercial organization, invest in its device fleet and supply chain, and fund R&D and clinical trials.
Use of Proceeds verify on EDGAR →
3 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (WS 10-Q) is open in full — no account needed.
Partner
Trade KMTS commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 3, 2026 · How we verify